Our goal is to improve patient outcomes in oncology by enabling much greater access to the highest precision diagnostic tests. This collaboration with Agilent in lung cancer has again demonstrated that Biofidelity’s molecular assays dramatically increase the effectiveness and speed of diagnosis, supporting early detection of disease, better targeting of therapies and improved patient monitoring. By combining diagnostic outperformance and rapid results in a simple, cost-efficient format using existing instrumentation, we believe we have the potential to bring high precision testing to many more NSCLC patients, substantially reducing the need for invasive biopsies.
Dr Barnaby Balmforth
Chief Executive Officer of Biofidelity
RELATED POSTS
![](https://biofidelity.com/hs-fs/hubfs/Imported_Blog_Media/heiner-dreismann-720x450-1200x627-q60.jpg?width=352&name=heiner-dreismann-720x450-1200x627-q60.jpg)
Biofidelity appoints Dr. Heiner Dreismann as Chairman
- Veteran Roche executive with more than 35 years of industry experience
- Pioneer in the early adoption of polymerase chain reaction (PCR) technology
- ...
![](https://biofidelity.com/hs-fs/hubfs/Steve-Blog-Picture.webp?width=352&name=Steve-Blog-Picture.webp)
Biofidelity appoints Stephen Miller as Chief Commercial Officer
Experienced US-based commercial leader joins Biofidelity prior to launch of disruptive cancer diagnostic platform
- US diagnostics executive with...